Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 16/20 | 0.66 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 3/20 | 0.42 |
| ▸ | TDO2 | P48775 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4550763 | 1.00 | PDE2A (0.66) | PDE2AHTR2AHTR2CHTR2BIDO1 | |
| SCHEMBL29685925 | 1.00 | PDE2A (0.66) | PDE2AHTR2AHTR2CHTR2BIDO1 | |
| SCHEMBL30557838 | 1.00 | PDE2A (0.66) | PDE2AHTR2AHTR2CHTR2BIDO1 | |
| SCHEMBL4233776 | 1.00 | PDE2A (0.66) | PDE2AHTR2AHTR2CHTR2BIDO1 | |
| Hydrochloric Acid SCHEMBL2715888 | 0.98 | PDE2A (0.64) | PDE2AHTR2AHTR2CHTR2BIDO1 | |
| SCHEMBL16043553 | 0.87 | PDE2A (0.51) | PDE2A | |
| SCHEMBL16044616 | 0.87 | PDE2A (0.51) | PDE2AHTR2AHTR2CHTR2B | |
| SCHEMBL16868139 | 0.85 | PDE2A (0.50) | PDE2AHTR2AHTR2CHTR2BIDO1 | |
| SCHEMBL20811529 | 0.85 | PDE2A (0.67) | PDE2AHTR2AHTR2CHTR2BIDO1 | |
| SCHEMBL22221342 | 0.85 | PDE2A (0.67) | PDE2AHTR2AHTR2CHTR2BIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240009169-A9 | PPARG Modulators for the Treatment of Osteoporosis | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2024-01-11 | — | — | US | disclosed |
| CN-112062730-B | 4-oxo-3, 4-dihydro-1, 2, 3-benzotriazines as modulators of GPR139 | 武田药品工业株式会社 | 2023-09-29 | — | — | CN | disclosed |
| US-20230072933-A1 | PPARG Modulators for the Treatment of Osteoporosis | SCRIPPS RESEARCH INST (US) | 2023-03-09 | — | — | US | disclosed |
| US-11173161-B2 | 4-oxo-3,4-dihydro-1,2,3-benzotriazine modulators of GPR139 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-11-16 | — | — | US | disclosed |
| EP-3536324-B1 | 4-OXO-3,4-DIHYDRO-1,2,3-BENZOTRIAZINES AS MODULATORS OF GPR139 | TAKEDA PHARMACEUTICALS CO (JP) | 2021-10-06 | — | — | EP | disclosed |
| CN-112062730-A | 4-oxo-3, 4-dihydro-1, 2, 3-benzotriazines as modulators of GPR139 | 武田药品工业株式会社 | 2020-12-11 | — | — | CN | disclosed |
| CN-107108531-B | 4-oxo-3, 4-dihydro-1, 2, 3-benzotriazines as modulators of GPR139 | 武田药品工业株式会社 | 2020-10-20 | — | — | CN | disclosed |
| US-10744117-B2 | PPARG modulators for the treatment of osteoporosis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2020-08-18 | — | — | US | disclosed |
| US-20200129518-A1 | 4-OXO-3,4-DIHYDRO-1,2,3-BENZOTRIAZINE MODULATORS OF GPR139 | TAKEDA CALIFORNIA, INC. | 2020-04-30 | — | — | US | disclosed |
| US-10561662-B2 | 4-oxo-3,4-dihydro-1,2,3-benzotriazine modulators of GPR139 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-02-18 | — | — | US | disclosed |
| US-20150152093-A1 | 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | NOVARTIS AG (CH) | 2015-06-04 | — | — | US | disclosed |
| US-8957093-B2 | N-biphenylmethylindole modulators of PPARG | THE SCRIPPS RESEARCH INSTITUTE (US) | 2015-02-17 | — | — | US | disclosed |
| US-8957068-B2 | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH | NOVARTIS AG (CH) | 2015-02-17 | — | — | US | disclosed |
| US-20140275083-A1 | 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | NOVARTIS AG (CH) | 2014-09-18 | — | — | US | disclosed |
| US-20140275083-A1 | 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | NOVARTIS AG (CH) | 2014-09-18 | — | — | US | disclosed |
| EP-2771337-A1 | 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | Novartis AG (CH) | 2014-09-03 | — | — | EP | disclosed |
| US-20140235620-A1 | 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | NOVARTIS AG (CH) | 2014-08-21 | — | — | US | disclosed |
| WO-2013046136-A1 | 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | NOVARTIS AG (CH) | 2013-04-04 | — | — | WO | disclosed |
| WO-2013046136-A1 | 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | NOVARTIS AG (CH) | 2013-04-04 | — | — | WO | disclosed |
| US-20120309757-A1 | N-BIPHENYLMETHYLINDOLE MODULATORS OF PPARG | SCRIPPS RESEARCH INSTITUTE, THE (US) | 2012-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275083-A1 | 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | IDH1, IDH3B, IDH3A | PDE2A 3092/4885HTR2A 4593/4885HTR2C 4292/4885 |
| US-20200129518-A1 | 4-OXO-3,4-DIHYDRO-1,2,3-BENZOTRIAZINE MODULATORS OF GPR139 | GPR139, GPR3, GPR84 | PDE2A 448/4885HTR2A 174/4885HTR2C 341/4885 |
| US-20120309757-A1 | N-BIPHENYLMETHYLINDOLE MODULATORS OF PPARG | CDK5, CDK5R1, PPARG | PDE2A 1200/4885HTR2A 1084/4885HTR2C 1009/4885 |
| US-20140235620-A1 | 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | IDH1, IDH3A, IDH3B | PDE2A 3316/4885HTR2A 4594/4885HTR2C 4156/4885 |
| US-10561662-B2 | 4-oxo-3,4-dihydro-1,2,3-benzotriazine modulators of GPR139 | GPR139, GPR3, GPR84 | PDE2A 448/4885HTR2A 174/4885HTR2C 341/4885 |
| US-20230072933-A1 | PPARG Modulators for the Treatment of Osteoporosis | PPARG, PPARA, PPARD | PDE2A 1531/4885HTR2A 2557/4885HTR2C 3715/4885 |
| US-20150152093-A1 | 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | IDH1, IDH3B, IDH3A | PDE2A 3092/4885HTR2A 4593/4885HTR2C 4292/4885 |
| US-11173161-B2 | 4-oxo-3,4-dihydro-1,2,3-benzotriazine modulators of GPR139 | GPR139, GPR3, GPR84 | PDE2A 448/4885HTR2A 174/4885HTR2C 341/4885 |
| US-10744117-B2 | PPARG modulators for the treatment of osteoporosis | PPARG, PPARA, PPARD | PDE2A 1531/4885HTR2A 2557/4885HTR2C 3715/4885 |
| US-20240009169-A9 | PPARG Modulators for the Treatment of Osteoporosis | PPARG, PPARA, PPARD | PDE2A 1531/4885HTR2A 2557/4885HTR2C 3715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.